Addition of obinutuzumab or rituximab to chlorambucil for chronic lymphocytic leukaemia

Share :
Published: 18 Jun 2013
Views: 4751
Dr Valentin Goede - University Hospital of Cologne, Germany

Dr Valentin Goede presented promising outcomes for elderly CLL patients at the 18th Congress of the European Hematology Association in Stockholm.

It has been an unresolved question whether (i) combination treatment with the chemotherapeutic drug chlorambucil plus a monoclonal CD20 antibody improves outcomes for such patients compared to treatment with chlorambucil alone and (ii) these patients benefit from the use of the novel CD20 antibody obinutuzumab (GA101) relative to the approved CD20 antibody rituximab.

The CLL11 trial conducted by the German CLL Study Group (GCLLSG) in collaboration with Hoffmann-La Roche for the first time compares directly the following treatments in elderly patients with comorbidities: GA101 plus chlorambucil, rituximab plus chlorambucil, and chlorambucil alone.


Visit ecancerNews to read more